1. Scrip
  2. >>Focus On Asia
  3. >>Japan

Japan Results Roundup: Global Mainstays And Forex Boost Top Lines

 
• By Lisa Takagi

Mostly strong global sales of mainstay drugs, along with a forex boost, helped Japan's major pharma firms in the fiscal third quarter and calendar year.

Japan's Q4 results
(Shutterstock)

Along with generally strong mainstay sales, the continued weakening of the yen boosted overseas sales at major Japanese pharma firms in the fiscal third quarter and full year ended 31 December. The Japanese currency was hovering around JPY148 to the US dollar in February 2024 but has fallen to around JPY153 this February.

Astellas Q3

Nine-Month Revenue (year-on-year (YoY) growth): JPY1,453.0bn ($9.48bn; +22.2%)

Core Operating Profit: JPY297.5bn (+44.1%)

Key Elements:

  • Solid growth of mainstays including Xtandi, Padcev, Xospata with a push from weaker forex rate.

Annual Revenue Forecast (FY24): JPY1,900.0bn (+5.6%)

(Revised up again from JPY1,800bn (in turn revised end Q2 from JPY1,650.0bn (+2.9%))

Key Events In Q4:

    Read the full article – start your free trial today!

    Join thousands of industry professionals who rely on Scrip for daily insights

    • Start your 7-day free trial
    • Explore trusted news, analysis, and insights
    • Access comprehensive global coverage
    • Enjoy instant access – no credit card required
    Start Free Trial

    Already a subscriber?

    More from Japan

    Can Japan’s Richest Person Save Cell Therapy’s Future?

     
    • By Lisa Takagi

    With financial help from the founder of Uniqlo, Japan’s leading facility for induced pluripotent stem cells is aiming to automate production to slash costs and kick-start R&D in the field.

    Citeline Japan Awards 2025 - Enter Now!

     
    • By Ian Haydock and Lisa Takagi

    The 14 July deadline for the Citeline Japan Awards 2025 in Tokyo is approaching fast, so here's a reminder to take a look at the categories and criteria and be sure to get those submissions in by this date. Sponsorship opportunities and tables for the event are also available.

    Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

     
    • By Lisa Takagi

    While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

    In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

     
    • By Sushmita Panda

    Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

    More from Focus On Asia

    Battle For Obesity Market Shifts Gears in India: Will Wegovy Trump Mounjaro?

     
    • By Anju Ghangurde

    Novo Nordisk debuts Wegovy in India, gears for pole position in obesity. The Danish group’s leadership doesn’t appear too perturbed about the head start for Lilly’s Mounjaro or the imminent arrival of generic semaglutide next year.

    Bitcoin Player Parataxis To Acquire Bridge Biotherapeutics After IPF Failure

     
    • By Jung Won Shin

    After the failure of its lead asset in a Phase II trial earlier this year, Korea's Bridge Biotherapeutics has accepted an acquisition offer from bitcoin group Parataxis.

    Chinese Developers Showcase Potentially Differentiated Weight Loss Assets At ADA

     
    • By Xu Hu

    Multiple Chinese firms presented at this year’s ADA meeting, with a focus on weight reduction efficacy for mostly early clinical stage assets. While limited information was given on lean mass preservation, several companies are progressing drugs and combos to address this need.